All In Biotech

Drug Trial Radar · NCT05852691

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

A Phase II, Multicenter, Randomized, Double-Blind Study of Tobemstomig/RO7247669 Combined With Nab-Paclitaxel Compared With Pembrolizumab Combined With Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

83

Actual

Start

Jul 18, 2023

Primary completion

Oct 15, 2026

Study completion Oct 15, 2026

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
May 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy and safety of a novel immunotherapy candidate, tobemstomig, in combination with nab-paclitaxel, for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-positive triple-negative breast cancer (TNBC).

Conditions

  • Breast Cancer

Interventions

  • TobemstomigDrug

    Participants will receive intravenous (IV) tobemstomig every 3 weeks (Q3W) until disease progression or until up to 24 months after the first treatment, whichever is sooner.

  • PembrolizumabDrug

    Participants will receive IV pembrolizumab Q3W until disease progression or until up to 24 months after the first treatment, whichever is sooner.

  • Nab-PaclitaxelDrug

    Participants will receive IV nab-paclitaxel weekly for 3 weeks, followed by 1 week off, until disease progression or until up to 24 months after the first treatment, whichever is sooner.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 24 months)

Locations

36 sites in 16 countries. Site status is shown where the registry gives one.

  • Cancer Blood and Specialty Clinic

    Los Alamitos, California

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Novant Health Presbyterain Medical Center

    Charlotte, North Carolina

  • Avera Cancer Institute

    Sioux Falls, South Dakota

  • Centro de Investigaciones Médicas y Desarrollo LC S.R.L

    Buenos Aires, Argentina

  • Sunshine Hospital

    St Albans, Victoria, Australia

  • Hospital Araujo Jorge

    Goiânia, Goiás, Brazil

  • Hospital do Cancer de Pernambuco - HCP

    Recife, Pernambuco, Brazil

  • Hospital de Cancer de Barretos

    Barretos, São Paulo, Brazil

  • Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda

    São Paulo, São Paulo, Brazil

  • Fakultni Thomayerova nemocnice

    Praha 4 - Krc, Czechia

  • Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH

    Essen, Germany

  • Dres. Andreas Köhler und Roswitha Fuchs

    Langen, Germany

  • Universitätsklinikum Ulm Am Michelsberg

    Ulm, Germany

  • Komarom-Eszergom Varmegyei Szent Borbala Korhaz

    Tatabánya, Hungary

  • Hadassah University Hospital - Ein Kerem

    Jerusaelm, Israel

  • Sheba Medical Center

    Ramat Gan, Israel

  • Ospedale Provinciale Santa Maria Delle Croci

    Ravenna, Emilia-Romagna, Italy

  • Ospedale San Raffaele

    Milan, Lombardy, Italy

  • Health Pharma Professional Research

    Mexico City, Mexico CITY (federal District), Mexico

  • OncoMed

    Mexico City, Mexico CITY (federal District), Mexico

  • Centro Médico Zambrano Hellion

    Monterrey, Nuevo León, Mexico

  • Centro Medico Monte Carmelo

    Arequipa, Peru

  • Oncosalud Sac

    Lima, Peru

  • Instituto Nacional de Enfermedades Neoplasicas

    Lima, Peru

  • Instituto Peruano de Oncología y Radioterapia

    Lima, Peru

  • ?wi?tokrzyskie Centrum Onkologii

    Kielce, Poland

  • Szpital Uniwersytecki w Krakowie, Oddzia? Kliniczny Kliniki Onkologii

    Krakow, Poland

  • Medical Oncology Centre of Rosebank

    Johannesburg, South Africa

  • Seoul National University Hospital

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Gangnam Severance Hospital, Yonsei University Health System

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Hospital Quiron de Madrid

    Pozuelo de Alarcón, Madrid, Spain

  • Hospital Universitario Virgen de La Arrixaca

    El Palmar, Murcia, Spain

  • National Taiwan Uni Hospital

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.